- Earth Science Tech has evolved into a diversified healthcare holding company with operations spanning telemedicine, compounding pharmacies, clinical support services and healthcare fulfillment.
- In addition, the company has actively reduced its share count through a series of share repurchases documented in SEC filings and share structure records.
- Earth Science Tech repurchased 3.7 million shares over the nine months ended December 31, 2025, spending approximately $647,000.
- Management continues to emphasize shareholder value through balance-sheet management alongside acquisitions and operating growth.
- The company is scheduled to present to investors at the Planet MicroCap Las Vegas 2026 conference in June.
For many investors evaluating companies on the OTC market, share structure often receives as much attention as revenue growth or acquisition activity. Earth Science Tech (OTC: ETST), a strategic holding company spanning telemedicine, pharmacies, clinical support services, and healthcare fulfillment, has increasingly distinguished itself in share structure and financial stability through a sustained program of share repurchases, which has reduced outstanding shares while the company simultaneously expands its healthcare-focused operating platform.
The company’s most recent Form 10-Q, covering the quarter ended December 31, 2025, provides a detailed look at the pace of those repurchases (https://ibn.fm/Gm12j). According to the filing, Earth Science Tech repurchased 1,143,000 common shares during the quarter for approximately…
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN